High Investment Medications
As novel therapies to address important medical needs are approved, the high costs for these medications — and especially cell and gene therapies — can raise sustainability and affordability concerns for employers, payers, and patients. High short-term investments present clinical and financial challenges that are magnified when the long-term health benefits are uncertain, patients switch employers or enroll in different health plans, or complex care coordination is needed. New payment policies and application of 21st century financial and technical tools can mitigate risk and affordability concerns. This Partnership Forum addressed payment and benefit challenges for high-investment medications and explored alternative payment reform, financial tools, and policy initiatives to improve the predictability, affordability and accessibility of high-investment treatments and help to ensure patients get the medications they need at a cost they can afford.
- Forum Program [PDF]
- Press Release
- Executive Summary - distributed in May
- Forum Proceedings - to come in Q4 of 2022
- Forum Webinar - to come in Q4 of 2022